| Type 2 Diabetes Mellitus |
1 |
1 |
| COVID-19 |
0 |
0.9 |
| Obesity |
0 |
0.44 |
| Comparative Effectiveness |
0 |
0.5 |
| Weight Loss |
0 |
0.42 |
| Heart Failure (HF) |
0 |
0.34 |
| COVID-19 and Diabetes |
0 |
0.99 |
| Heart |
0 |
0.33 |
| Pandemic |
0 |
0.33 |
| Social Determinants of Health |
0 |
0.3 |
| Weight Management |
0 |
0.3 |
| Cardiovascular Risk Management |
0 |
0.6 |
| Adverse Effects |
0 |
0.17 |
| Hand |
0 |
0.17 |
| Health Care Inequities |
0 |
0.17 |
| Mechanical Ventilation |
0 |
0.17 |
| Patient Safety |
0 |
0.16 |
| Foot Care |
0 |
0.12 |
| Hemoglobin A1c |
0 |
0.12 |
| Type 1 Diabetes Mellitus |
0 |
0.95 |
| Cardiovascular disease |
0 |
0.08 |
| Diabetic Ketoacidosis |
0 |
0.08 |
| Dorsum |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Health Care Delivery |
0 |
0.08 |
| Health Care Quality, Access, and Evaluation |
0 |
0.8 |
| Hemoglobin |
0 |
0.08 |
| Hyperglycemia |
0 |
0.08 |
| Inpatient Care |
0 |
0.08 |
| Insulin Therapy |
0 |
0.65 |
| Organ Failure |
0 |
0.08 |
| Pedal |
0 |
0.08 |
| Precision Medicine |
0 |
0.08 |
| Psychosocial |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Respiratory Failure |
0 |
0.08 |
| SGLT2 Inhibitor |
0 |
0.08 |
| Stigma |
0 |
0.08 |
| Stress |
0 |
0.08 |
| Biologic Therapy |
0 |
0.06 |
| Genomic Medicine |
0 |
0.06 |